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Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disease resulting from motor neuron degeneration that
causes muscle weakness, paralysis, and eventually respiratory failure. We investigated whether recombinant adeno-
associated virus encoding human hepatocyte growth factor (rAAV-HGF) could generate beneficial effects in two
mouse models with neuromuscular problems when intrathecally delivered to the subarachnoid space. We chose
AAV serotype 1 (rAAV1) based on the expression levels and distribution of HGF protein in the lumbar spinal cord
(LSC). After a single intrathecal (IT) injection of rAAV1-HGF, the protein level of HGF in the LSC peaked on day 14
and thereafter gradually decreased over the next 14 weeks. rAAV1-HGF was initially tested in the mouse nerve crush
model. IT injection of rAAV1-HGF improved mouse hindlimb strength and rotarod performance, while histological
analyses showed that the length of regenerated axons was increased and the structure of the neuromuscular
junction (NMJ) was restored. rAAV1-HGF was also evaluated in the SOD1-G93A transgenic (TG) mouse model. Again,
rAAV1-HGF not only improved motor performance but also increased the survival rate. Moreover, the number and
diameter of spinal motor neurons (SMNs) were increased, and the shape of the NMJs restored. Data from in vitro
motor cortical culture experiments indicated that treatment with recombinant HGF protein (rHGF) increased the
axon length of corticospinal motor neurons (CSMNs). When cultures were treated with an ERK inhibitor, the effects
of HGF on axon elongation, protein aggregation, and oxidative stress were suppressed, indicating that ERK
phosphorylation played an important role(s). Taken together, our results suggested that HGF might play an
important role(s) in delaying disease progression in the SOD1-G93A TG mouse model by reducing oxidative
stress through the control of ERK phosphorylation.
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Introduction
ALS is a neurodegenerative disease, in which the motor
neurons of the central nervous system degenerate pro-
gressively [13, 23, 49]. A variety of chemicals, recombin-
ant proteins, and gene therapies have been explored to
develop treatment methods for ALS, but to date, only
two small molecules, riluzole and edaravone, have been
approved by the FDA [3, 5, 39]. Their therapeutic effects
are relatively low: riluzole delays the time to tracheos-
tomy by 2 to 3 months, and edaravone improves the
ALSFRS-R score by 33%. There is still a high unmet
need for a medical solution to this fatal disease.
In this study, we investigated whether HGF could be
used to treat ALS in the context of AAV-based gene ther-
apy. Since its discovery in 1984, HGF has been shown to
contain multiple bioactivities, promoting cell proliferation,
morphogenesis, anti-fibrosis, anti-inflammation, and
angiogenesis, among others [17, 28, 31, 32, 40, 52, 57].
When HGF binds to the Met receptor, a variety of intra-
cellular signaling pathways are activated, involving PI3K,
JNK, p38, and/or ERK, triggering different biological reac-
tions depending on the cell type [36, 37, 50]. HGF is also a
neurotrophic factor in that it can induce the development,
proliferation, and differentiation of neuronal cells [19, 30,
34, 41, 45, 46]. It has also been reported that the
HGF-Met complex was abnormally sequestered in fALS
patients [20]. In the SOD1-G93A TG mouse model, dis-
ease progression has been delayed when HGF or Met ex-
pression was additionally introduced by generating double
TG mice, or when rHGF was intrathecally delivered, indi-
cating that HGF might play an important role(s) in ALS
[10, 16, 48].
HGF-expressing plasmid DNA was used in the phase I
trial for ALS [47]. A single intramuscular administration
of this plasmid DNA in 18 ALS patients has been proven
to be safe, with no significant adverse effects. According
to the ALSFRS-R scores, the conditions of patients ap-
peared to stabilize or even improve in 50% of patients—al-
beit temporarily—during the first 2 to 3months following
injection. The same plasmid was also used for diabetic
peripheral neuropathy and critical limb ischemia, and gen-
erated highly positive results with virtually no drug-related
adverse effects, indicating the possibility of employing
plasmid DNA expressing HGF for a broad range of neuro-
muscular or neuroischemic diseases [1, 11, 14, 21, 22].
This study employed AAV, as an alternative method of
delivering the HGF gene [7, 59]. AAV can drive relatively
long-term expression in vivo and deliver the transgene
to a variety of cell types, including non-dividing cells
through capsid pseudotyping [7]. We found that among
4 serotypes tested, serotype 1 (rAAV1) most effectively
delivered the gene to the ventral horn of the LSC when
introduced to the subarachnoid space by IT delivery.
When evaluated in two mouse models—the sciatic nerve
crush and SOD1-G93A TG mouse models—
rAAV1-HGF ameliorated deficits in motor functions as
measured by several behavioral tests and regenerated
impaired NMJ structure [53]. Consistent with these ob-
servations, HGF was found to increase the axon lengths
of CSMNs in vitro. Data from experiments involving
specific chemical inhibitors revealed that phosphoryl-
ation of ERK is an important player for HGF-generated
effects. Our results suggested that the HGF gene may be
a good starting point for developing therapeutic agents
for ALS and that rAAV vector in particular might be a
useful gene delivery vehicle.
Materials & methods
Animals
C57BL/6 mice were purchased from Orient Bio Inc.
(Gyeonggi-do, Korea). B6SJL-TG(SOD1-G93A)1Gur/J
mice (MGI ID: 2183719) were purchased from The Jack-
son Laboratory [12, 51, 55]. Mice were fed ad libitum
and entrained to a standard light-dark cycle. All experi-
mental protocols adhered to the regulations of the Seoul
National University Institutional Animal Care and Use
Committee (IACUC).
Adeno-associated virus
In this study, a gDNA-cDNA-hybrid sequence that could
express HGF723 (dHGF) and HGF728 (cHGF) was gen-
erated using human genomic DNA as previously de-
scribed [6, 38]. This hybrid sequence has cDNA
sequences of 18 exons of the HGF gene, containing a
part of intron 4 between exon 4 and exon 5. Since the
length of intron 4 is too long to produce viral vectors,
4329 base pairs of intron 4 were deleted using
site-directed mutagenesis by polymerase chain reaction
(PCR). This chimeric sequence was then inserted into
the ITR (inverted terminal repeat) region of
pAAV-MCS, a plasmid containing multiple cloning sites
purchased from Agilent Technologies, to generate
pAAV-HGF. To produce rAAV2-HGF, equal amounts of
three plasmids (rep/cap-expressing plasmid, pAAV-HGF,
and helper plasmid) were co-transfected into 1 × 106
HEK293T cells using AAV Helper-Free System (Agilent
Technologies). 1.23 × 108 GC (genome copies) of
rAAV2-HGF were then transduced into 1.6 × 105 C2C12
cells. Forty-eight hours later, the supernatant was col-
lected followed by ELISA specific to human HGF
(hHGF). At the same time, total RNAs were isolated and
subjected to RT-PCR using Expand High Fidelity PCR
System (Sigma). Primers used for PCR were as follows;
5′-CAAATGTCAGCCCTGGAGTTCCATGA-3′ (for-
ward); 5′-CTGGATTGCTTGTGAAACACCAGGGT-3′
(reverse). PCR products were then run on NuPAGE 4–
12% Bis-Tris Protein Gels (Thermofisher). rAAV2-MCS
lacking the HGF sequence (rAAV2-C) was used as a
Lee et al. Acta Neuropathologica Communications            (2019) 7:14 Page 2 of 18
negative control. For animal studies, rAAV (serotype 1,
2, 5, and 6) with a higher titer (1 × 1012 GC/ml) was pro-
duced by a contract manufacturing company called
CdmoGen (Chungbuk, Korea).
Sciatic nerve crush
The sciatic nerves of C57BL/6 mice were exposed, and
nerve crush injury was induced with fine hemostatic for-
ceps (FST), as described previously [6, 24]. Mice were
exposed to isoflurane at 4–5% until anesthesia was in-
duced, with concentration reduced to 1.5% during sur-
gery. Behavioral tests were performed once a week for
four weeks. For histological analysis, the sciatic nerves
and tibialis anterior (TA) muscles were collected five
days after surgery.
Behavioral tests
The motor function of mice was evaluated using the
rotarod test, wire hanging test, and grip strength test.
For the rotarod test, the latency to fall from the rotating
rod was recorded. The speed of the rod was accelerated
from 4 rpm to 40 rpm for 5 min, as described previously
[15, 25, 44]. For the wire hanging test, mice were placed
upside down under wire mesh. The latency to fall was
recorded. The maximum latency was set to 1 min. Grip
strengths of the forelimb and hindlimb were measured
with a grip strength meter (Nidec-Shimpo). Mice were
pre-trained for a week for each behavioral test. Each test
was performed three times and values were averaged.
Primary motor cortical cultures
Cerebral motor cortices of mice were isolated, and cells
were incubated as described previously [18]. Six-well cell
culture plates (SPL) pre-coated with 0.1 mg/ml of PDL
(Sigma) were incubated overnight at 37 °C, followed by
two washings with distilled water (Sigma). Motor corti-
ces of non-TG or TG mice at P3 were collected using
fine forceps (FST) into dissociation solution (DS) con-
taining magnesium chloride (Sigma), Hepes (Gibco), so-
dium sulfate (Sigma), potassium sulfate (Sigma),
kyneuric acid (Sigma), glucose (Sigma), APV (Sigma),
penicillin/streptomycin (P/S) (Gibco), and B27 (Gibco).
Cells were then dissociated in a papain solution
(Worthington Biochem) for 15 min, and incubated in in-
hibitor solution containing ovomucoid (Sigma) for 1
min. After being washed with Opti-MEM (Gibco) solu-
tion containing APV (Sigma) and B27, 3.2 × 105 cells
were seeded with serum-free media (SFM) containing
BSA, L-glutamine (Sigma), P/S, glucose, and B27 in neu-
robasal media (Gibco). Cells were then treated with in-
hibitors for Met (PHA665752), ERK (U0126), PI3K
(LY294002), p38 (SB203580), and JNK (SP600125).
Thirty minutes later, cells were cultured in the presence
of 100 ng/ml of rHGF (R&D Systems). 3 days later, cells
were subjected to immunocytochemistry (ICC) assay.
Western blot
Total proteins were isolated using RIPA Buffer (Cell Sig-
naling Technology) and Protease/Phosphatase Inhibitor
Cocktail (Cell Signaling Technology), followed by poly-
acrylamide gel electrophoresis on NuPAGE 4–12%
Bis-Tris Protein Gels (Thermofisher) using 10–20 μg of
protein. Gels were transferred to the PVDF membrane
(GE Healthcare) and blocked with 0.1% TBST solution
containing 5% skim milk (Difco) for 1 h. Membranes
were incubated with 0.1% TBST solution containing 5%
BSA and primary antibodies for 1 h, then treated with
0.1% TBST solution containing 5% skim milk for 1 h.
HRP conjugated anti-rabbit or anti-mouse IgG (Sigma)
was used as a secondary antibody. Membranes were in-
cubated with Immobilin Western Chemiluminescent
HRP Substrate (Millipore) for 1 min and developed on
X-ray film (AGFA).
Immunohistochemistry (IHC)
The sciatic nerves, LSCs, and TA muscles were fixed in
4% paraformaldehyde (Sigma) at 4 °C overnight. After be-
ing washed three times with 0.1M PBS, the tissues were
immersed in 0.1M PBS containing 30% sucrose (Sigma)
at 4 °C overnight, followed by cryopreservation in OCT
compound (Sakura Tissue Tek). Samples were then cryo-
sectioned using Cryostat (Leica). After 1 h incubation in
blocking solution containing 2% BSA, 5% normal donkey
serum (Jackson ImmunoResearch), and 0.1% Triton
X-100 (Samchun), samples were treated with blocking so-
lution containing primary antibodies for 1 h, and then
with blocking solution containing secondary antibodies
for 1 h. IgG Alexa Fluor (Invitrogen) was used as a sec-
ondary antibody. After mounting tissue sections on micro-
scope slides (Fisher Scientific) with DAPI (Vectashield),
immunofluorescence was observed using LSM 700 con-
focal laser scanning microscopy (Carl Zeiss).
Immunocytochemistry (ICC)
Cells were fixed in 4% paraformaldehyde for 10 min at
room temperature. After being washed three times with
PBS, cells were immersed in 0.1 M PBS containing 2%
Triton X-100 for 5 min at 4 °C, followed by one hour in-
cubation in blocking solution with 2% normal donkey
serum and 1% BSA. Cells were then treated with block-
ing solution containing primary antibodies for 1 h,
followed by another 1-h incubation in blocking solution
with secondary antibodies. IgG Alexa Fluor was used as
a secondary antibody. After mounting cells on micro-
scope slides with DAPI, immunofluorescence was
observed using LSM 700 confocal laser scanning
Lee et al. Acta Neuropathologica Communications            (2019) 7:14 Page 3 of 18
microscopy. The axon length of CSMNs was measured
using Fiji software (NIH).
Quantitative real time PCR (q-RTPCR)
The transgene copy number of SOD1-G93A TG mice
was measured using q-RTPCR, as described previously
[2]. For transgene (hSOD1), the primers used for PCR
were as follows; 5′-CATCAGCCCTAATCCATCTGA-3′
(forward); 5′-CGCGACTAACAATCAAAGTGA-3′ (re-
verse). For reference gene (IL2), the primers used for
PCR were as follows; 5′-CTAGGCCACAGAATT-
GAAAGATCT-3′ (forward); 5′-GTAGGTGGAAATTC-
TAGCATCATCC-3′ (reverse). After 40 cycles of qPCR
using TB Green (Takara), the difference of threshold
cycle (ΔCT) was calculated, and mice with values be-
tween 6.6 and 7.2 were used.
Cell viability assay
1.6 × 105 cells were seeded on PDL-coated 48-well cell
culture plates (SPL) and incubated for 3 days. After be-
ing washed two times with warm PBS, cells were incu-
bated with SFM containing 10% WST1 (AbFrontier) for
1 h at 37 °C. Absorbance was measured at 440 nm using
a Magellan microplate reader (Tecan).
Enzyme-linked immunosorbent assay (ELISA)
To measure the HGF protein level in vitro, 1.6 × 105
C2C12 cells were transduced with 5 × 1013 GC of
rAAV2-HGF. Forty-eight hours later, supernatants were
collected followed by ELISA specific to human HGF
(R&D Systems). To measure the in vivo expression of
HGF, C57BL/6 P60 mice were intrathecally injected with
5 × 109 GC of rAAV1-HGF. The LSCs were collected 1,
2, 4, 8, 12, and 16 weeks after injection. Total proteins
were then extracted using RIPA Buffer and Protease/
Phosphatase Inhibitor Cocktail, followed by ELISA for
hHGF. Absorbance was measured at 450 nm, and wave-
length correction was made at 540 nm using a Magellan
microplate reader.
Reactive oxygen species (ROS) detection assay
6.4 × 104 cells were seeded on PDL-coated 96-well cell
culture plates (Nunc) and incubated for 3 days. ROS
levels were measured using a ROS Detection Assay Kit
(Abcam). Cells were incubated with detection solution
for 1 h at 37 °C. Pyocianin was used as a ROS inducer,
while N-acetyl-L-cysteine was used as a ROS scavenger.
Absorbance was measured using a Magellan microplate
reader.
Microarray assay
Motor cortical cells were treated with 100 ng/ml of
rHGF, and total RNAs were isolated followed by Micro-
array analysis using Affymetrix Genechip (Thermofisher).
After data extraction, RMA (robust multi-array average)
normalization was performed, followed by DEG (differen-
tially expressed gene) analysis. Out of selected DEGs,
functional annotation was performed based on GO (gene
ontologies) hierarchy and KEGG/BioCarta pathways. Se-
lected genes were clustered according to the classification
from the previous report [49].
Statistical analysis
All values are presented as mean ± standard error mean
(SEM). Differences between two values were analyzed by
Student’s t-tests. Differences between three or more
values were analyzed by one-way ANOVA followed by
Tukey’s post-hoc test. For values containing temporal
factors, two-way ANOVA was performed followed by
Tukey or Sidak’s post-hoc test.
Results
Construction of rAAV vectors expressing human HGF
In this study, we tested whether an HGF-expressing rAAV
vector could facilitate the regeneration of motor neurons
and alleviate disease progression of ALS when delivered to
the subarachnoid space through IT injection. AAV used in
this study was designed to express two isoforms of human
HGF—HGF723 (or dHGF) and HGF728 (or cHGF)—as in
the case of our bodies [6]. In order to simultaneously ex-
press two isoforms, we used the gDNA-cDNA-hybrid se-
quence similar to that described by Cho et al. (Additional
file 1: Figure S1a). This chimeric sequence was inserted
into pAAV-MCS containing multiple cloning sites, result-
ing in pAAV-HGF.
To produce rAAV vectors, equal amounts of three
plasmids (pAAV-HGF, rep/cap-expressing plasmid, and
helper plasmid) were co-transfected into 1 × 106
HEK293T cells, initially producing AAV serotype 2 [4].
Seventy-two hours later, the supernatant was collected
and viral titer was determined as described previously
[29]. To determine whether rAAV vectors could indeed
produce RNAs of two HGF isoforms, 1.6 × 105 C2C12
cells were transduced with 1.23 × 108 GC of rAAV, and
total RNAs were isolated 48 h later followed by RT-PCR.
A control virus—rAAV2-C lacking the HGF sequence—
did not produce any HGF RNA, whereas two HGF RNA
species, each for HGF723 and HGF728, were readily
detectable in cells transduced with rAAV2-HGF
(Additional file 1: Figure S1b).
To test whether HGF proteins were indeed produced
from rAAV vectors, 8 × 104 C2C12 cells were transduced
with 5 × 1013 GC of rAAV, and total proteins were isolated
48 h later followed by ELISA specific to human HGF pro-
teins. rAAV2-HGF produced 159.13 ± 23.92 ng/mg of
HGF, while no HGF was detectable in cells transduced
with a control vector. (Additional file 1: Figure S1c).
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Comparison of four AAV serotypes
Different subtypes of AAV have been shown to possess
different tropism. To select an appropriate AAV serotype
that could be used for gene transfer to the spinal cord,
four serotypes of AAV (rAAV-1, − 2, − 5, and − 6) were
prepared as described above, and 4.12 × 108 GC of each
AAV were injected into the LSC. Four weeks later, total
proteins were extracted from the LSC, and the expres-
sion level of HGF was compared using ELISA. As sum-
marized in Fig. 1a, mice injected with rAAV1-HGF
produced the highest level of HGF protein (621.89 ±
112.98 pg/mg), and other serotypes generated 7- to
17-fold lower amounts, 86.25 ± 7.59 pg/mg for rAAV6,
35.54 ± 4.87 pg/mg for rAAV2, and 80.15 ± 17.94 pg/mg
for rAAV5 (Fig. 1a).
To determine the tissue distribution of transgene
expression from different AAV vectors inside the
LSC, different subtypes of AAV expressing GFP were
used because it was technically difficult to analyze
human HGF by IHC. Four weeks after IT injection of
AAV vectors, tissue samples were taken and
GFP-expressing cells were measured by IHC.
rAAV1-GFP transduced the largest area of the ventral
horn, while rAAV2 or rAAV6 expressed GFP primar-
ily on the surface of white matter (Fig. 1b). Taken to-
gether, AAV1 appeared to be the most effective
serotype for IT gene delivery, and thus was used for
further experiments.
Kinetics of HGF expression from rAAV1-HGF
To determine how the HGF expression level changed
over time, 5 × 109 GC of rAAV1-HGF were injected
into the LSC of 2-month-old C57BL/6 mice, and total
proteins were isolated, followed by ELISA. One week
after injection, 1.98 ± 0.95 ng/mg of hHGF were de-
tectable, and the level was the highest after two
weeks (2.44 ± 1.37 ng/mg), thereafter gradually de-
creasing over time until 16 weeks after injection
(0.95 ± 0.58 ng/mg) (Fig. 1c). A control virus lacking
the HGF sequence did not produce any HGF protein.
While hHGF was not detectable in the motor cortex
and serum, 170.17 ± 155.95 pg/mg were observed in
the TA (Additional file 1: Figure S1d).
To investigate whether the HGF proteins expressed
from rAAV1-HGF could increase the phosphorylation of
Met, a receptor for HGF, 5 × 109 GC of rAAV1-HGF
were intrathecally injected into C57BL/6 mice at P60,
Met phosphorylation levels were measured 7 days later
using IHC. As shown in Fig. 1d, SMNs were labeled with
NeuN (red) and ChAT (green). In mice injected with
rAAV1-C, 37.32 ± 0.02% of SMNs were co-stained with
p-Met. The number of p-Met-positive SMNs was in-
creased to 58.09 ± 0.01% in the rAAV1-HGF group
(Fig. 2e). These results indicated that HGF proteins
expressed from rAAV1-HGF could indeed augment the
phosphorylation of Met.
Effects of rAAV1-HGF on the sciatic nerve crush model
We first used the sciatic nerve crush mouse model to
quickly check the effects of intrathecally delivered
rAAV1-HGF on nerve damage in general [53]. Crush in-
jury was introduced in 2-month-old C57BL/6 mice, and
5 × 109 GC of virus were intrathecally injected immedi-
ately. As shown in Fig. 2a-b, rAAV1-HGF significantly
improved hindlimb strength and rotarod performance
from 10 days after nerve crush, and these effects were
maintained until the end of the experiment on day 28.
These results suggested that rAAV1-HGF could promote
functional recovery after sciatic nerve crush when deliv-
ered into the spinal cord.
It is well established that when the sciatic nerve is in-
jured, Wallerian degeneration occurs and axons regener-
ate again as time goes by [42]. Therefore, we used IHC to
examine whether rAAV1-HGF had effects on nerve regen-
eration in the areas of the nerve damage. Five days after
nerve injury, the sciatic nerve was collected, and labeled
with SCG10, a marker for the regenerating axon [43].
When the length of the regenerated sciatic nerve was
measured, rAAV1-C showed a 2.11 ± 0.09mm increase
from the damaged site, while in the rAAV1-HGF group, it
was 37.91% higher at 2.91 ± 0.27mm (Fig. 2c-d).
The presynaptic terminal of the sciatic nerve forms NMJs
with the postsynaptic end plate of the muscle to transmit
the contractile signal to the muscle [53]. Therefore, TA
muscle connected to the sciatic nerve was analyzed by
IHC. In a normal state, the NMJ is pretzel-shaped and has
well-preserved integrity. After nerve injury, however, the
shape of the NMJ becomes abnormal and the degree of in-
tegrity decreases (Fig. 2e-f). Compared with the sham
group to which the nerve injury was not introduced, the
proportion of fully innervated NMJs in the rAAV1-C group
was reduced 2.34-fold, and that of abnormally shaped NMJs
was increased 7.75-fold. On the other hand, in the
rAAV1-HGF group, the proportion of fully innervated
NMJs increased by 69.7%, and that of denervated NMJs de-
creased 3.83-fold in comparison to the rAAV1-C group
(Fig. 2g-h). The average α-BTX area was decreased by
41.75% in the rAAV1-C group compared to the sham
group, but was increased by 56.76% in the rAAV1-HGF
group. These results suggested that IT injection of
rAAV1-HGF could promote the regeneration of neurons
and re-establishment of NMJs possibly by acting on the cell
body of motor neurons located in the spinal cord.
Effects of rAAV1-HGF in SOD1-G93A TG mouse model
Encouraged by the above results, the effects of
rAAV1-HGF were also tested in the SOD1-G93A TG





Fig. 1 IT administration of rAAV1-HGF promoted functional recovery in the sciatic nerve crush mouse model. a 4.12 × 108 GC of rAAV1, 2, 5, or 6-
HGF were intrathecally injected into C57BL/6 mice at postnatal day 60 (P60). The LSCs were collected and total proteins were isolated 4 weeks
after injection, followed by ELISA specific to human HGF (hHGF). For statistical analysis, one-way ANOVA was performed, followed by Tukey’s
post-hoc test. ****p < 0.0001 for rAAV1 vs. other serotypes. b 1.4 × 109 GC of four serotypes were intrathecally injected into 2-month-old C57BL/6
mice. The LSCs were collected 4 weeks after injection. Tissues were fixed, followed by IHC assay using an antibody specific to GFP (green). The
boundary between white and grey matter is distinguished by dotted lines, and white matter is indicated by white arrows. c 5 × 109 GC of rAAV1-
HGF were intrathecally injected into 2-month-old C57BL/6 mice. The LSCs were collected 1, 2, 4, 8, 12, and 16 weeks after IT injection and
subjected to ELISA for hHGF. For statistical analysis, two-way ANOVA was performed, followed by Sidak’s post-hoc test. The p-value between the
two groups was 0.0002. d C57BL/6 mice at P60 were intrathecally injected with 5 × 109 GC of rAAV1-C or rAAV1-HGF. One week later, LSCs were
collected and subjected to IHC assay. Antibodies specific to ChAT (green) and NeuN (red) were used to label SMNs, together with those for p-
Met (magenta). In low magnification panels, the boundary between white and grey matter is distinguished by dotted lines. In merge panels, p-
Met-expressing SMNs are indicated by white arrows. e The proportion of SMNs expressing p-Met per total SMNs was measured and represented
as a bar graph. For statistical analysis, Student’s t-test was performed. ****p < 0.0001. In bar graphs, values are represented as mean ± SEM. Scale
bar: b = 100 μm, d = 100 μm for low magnification panels and 20 μm for the others







Fig. 2 (See legend on next page.)
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mouse model, the most commonly used animal model
for ALS. First, we investigated whether HGF proteins
expressed from rAAV1-HGF could also increase the phos-
phorylation of Met in SOD1-G93A TG mice. 5 × 109 GC
of rAAV1-HGF were intrathecally injected to
SOD1-G93A TG mice at P60, and the levels of Met phos-
phorylation were measured 40 days later using IHC (Add-
itional file 1: Figure S2a). In non-TG mice, 35.24 ± 0.55%
of SMNs were co-stained with p-Met. The number of
p-Met-positive cells was lowered in TG mice injected with
a control vector, rAAV1-C, to 29.98 ± 0.54%, but increased
to 59.65 ± 1.35% in the rAAV1-HGF group (Additional file
1: Figure S2b). These findings suggested that the HGF
proteins expressed from rAAV1-HGF could indeed in-
crease the phosphorylation of Met in this mouse model.
To test whether rAAV1-HGF could exert any effect on
disease progression of SOD1-G93A TG mice, body
weight was measured and behavioral tests were per-
formed once every week until P158 after injecting
rAAV1-HGF into the LSC of TG mice at P60. IT deliv-
ery of rAAV1-HGF did not affect the rate of weight loss
(Fig. 3e), but significant improvements were observed in
rotarod, hanging wire, and grip strength tests (Fig. 3a-d).
In addition, survival rate was increased from 20 to
66.67% at P150, and median survival was also increased
by 6.53% from 145.5 days to 155 days (Fig. 3f). These re-
sults suggested that IT delivery of rAAV1-HGF might
slow disease progression and improve survival rate in
this mouse model.
Effects of rAAV1-HGF on SMNs and NMJs in the SOD1-
G93A TG mouse model
We tested whether IT injection of rAAV1-HGF could
delay degeneration of SMNs in SOD1-G93A TG mice.
5 × 109 GC of rAAV1-HGF were injected into the LSCs
of SOD1-G93A TG mice at P60, and the LSCs were col-
lected 40 days later (P100) followed by IHC. When
compared to the non-TG group, the rAAV1-C group
showed the number of SMNs in the ventral horn re-
duced 2.07-fold, the ratio of SMNs to total cells de-
creased by 58.65%, and the diameter of SMNs
diminished by 39.83% (Fig. 4a). Although rAAV1-HGF
did not increase the diameter of SMNs, the number of
SMNs was increased 2.36-fold and the ratio of SMNs to
total cells was increased by 67.11%, compared to the
rAAV1-C (Fig. 4b-d).
We also examined whether changes in SMNs by the
rAAV1-HGF could lead to improvements in connected
axon terminals and muscles. Similar to the experiments
described above (Fig. 2e-h), the NMJ was observed and
the weight of TA was measured. Compared to the
non-TG group, in the rAAV1-C group, the proportion of
fully innervated NMJs was decreased by 25.48%, the
level of abnormal-shaped NMJs was increased 3.5-fold,
and the weight of TA was decreased by 35.42%. When
rAAV1-HGF was injected, however, the proportion of
pretzel-shaped NMJs was increased by 32.58% (Fig.
4e-f ), and the weight of TA, which was decreased by
muscular atrophy in the rAAV1-C group, was increased
by 38.42% (Fig. 4g). No visible change was observed in
the degree of NMJ integrity in the rAAV1-HGF group.
These results indicated that IT delivery of rAAV1-HGF
could promote the protection of peripheral nerves and
NMJs as well as SMNs.
Effects of rHGF on axonal outgrowth of CSMNs
The above data showed that IT delivery of rAAV1-HGF
could improve motor functions and survival rates of
SOD1-G93A TG mice, presumably by slowing down the
degeneration of SMNs and restoring the morphology of
NMJs. Since the interaction of HGF with lower motor
neurons has been relatively well established compared
to the interaction of HGF with upper motor neurons
(See figure on previous page.)
Fig. 2 IT delivery of rAAV1-HGF facilitated the regeneration of the sciatic nerves and TA muscles after sciatic nerve crush. a-h Using 2-month-old
C57BL/6 mice, sciatic nerve crush was induced, and 5 × 1011 GC of rAAV1-C or rAAV1-HGF were intrathecally injected into the LSC. Behavioral
tests were performed once a week for 28 days (a-b). For IHC assay, the sciatic nerves and TA muscles were collected 5 days after nerve crush (c-f).
a Hindlimb strength was measured 1, 7, 10, 14, 21, and 28 days after nerve crush. Value at day 0 was measured before nerve crush. b Mean
latency to fall from the rotarod was measured 1, 7, 10, 14, 21, and 27 days after nerve crush. Value at day 0 was measured before nerve crush. In
Fig. 2a-b, two-way ANOVA was performed, followed by Tukey’s post-hoc test. c Representative images of the sciatic nerves from mice treated
with rAAV1-C or rAAV1-HGF after nerve crush. Antibodies specific to TUJ1 and SCG10 were used as markers for neurons and regenerating axons,
respectively. Crush sites are indicated by dotted lines, and the tip of SCG10 signals is indicated by white arrows. Proximodistal direction is
indicated by dotted lines. d After sciatic nerve crush, lengths of regenerated nerves were measured using Fiji software and represented as a bar
graph. For statistical analysis, Student’s t-test was performed. e-f An antibody specific to UCHL1 was used as a marker for presynaptic terminals,
whereas that of α-bungarotoxin (α-BTX) was used for postsynaptic end plates [9]. The shapes of NMJs were analyzed to determine whether they
were pretzel-shaped or distorted (e). The integrity of NMJs was determined by measuring to what degree presynaptic terminals merged with
postsynaptic end plates (f). g-i After sciatic nerve crush, the shape (g) and integrity (h) of NMJs and average α-BTX area (i) were measured. For
graphs, values are represented as mean ± SEM. In Fig. 2g-h, two-way ANOVA was performed, followed by Tukey’s post-hoc test. In Fig. 2g,
****p < 0.0001 for modified NMJ, ####p < 0.0001 for pretzel-shaped NMJ. In Fig. 2h, **p < 0.01 and ****p < 0.0001 for fully innervated NMJ,
####p < 0.0001 and n.s. > 0.05 partially innervated NMJ. In Fig. 2i, one-way ANOVA was performed, followed by Tukey’s post-hoc test. For
the remaining bar graphs, *p < 0.05, **p < 0.005, ***p < 0.001, ****p < 0.0001. Scale bars: c = 200 μm; d-e = 20 μm
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[8, 54, 56], we were interested in testing the possible
involvement of upper motor neurons by using the
motor cortical cultures system consisting of CSMNs
and glial cells [18, 35].
The motor cortices were isolated from P3 non-TG or
TG mice, and 2 × 104 cells were cultured on a 24-well
plate. Three days later, cells were fixed, followed by IHC
analysis. CSMNs were labeled with UCHL1 and Ctip2,
and Fiji software was used to measure the axon length
of CSMNs [58] (Fig. 5a).
Since CSMNs have previously been shown to produce
HGF which may give experimental noise, the effects of
endogenously expressed HGF were first tested using
PHA665752, a chemical inhibitor of Met. When cells
were treated with 1 μM of PHA665752 for 3 days, the
axon length of CSMNs was reduced 3.42-fold in the
non-TG group and 2.33-fold in the TG group (Fig. 5b).
This result indicated that endogenously expressed HGF
could positively affect the axonal outgrowth of CSMNs.
When 100 ng/ml of rHGF were added to the culture
for 3 days, however, the axon length of CSMNs was in-
creased by 48.61% in the non-TG group, and by 124.73%
in the TG group (Fig. 5c). When PHA665752 was
co-treated with rHGF, the HGF-mediated increase of
CSMNs’ axon length was inhibited by 127.7% in the
non-TG group, and by 120.82% in the TG group (Fig.
5d). This is consistent with the data in Fig. 7a-b showing
activation or inhibition of phosphorylation of the Met
protein by HGF or PHA665752. These results suggested
that activation of the HGF-Met signaling pathway might
be involved in the promotion of axonal outgrowth of
CSMNs.
Effects of inhibition of ERK, PI3K, and p38 on axonal
outgrowth of CSMNs
Several signaling pathways have been shown to be
turned on upon interaction between HGF and Met re-
ceptor. To identify the key pathway involved in the regu-
lation of the HGF-mediated axonal outgrowth of
CSMNs, 2 × 104 cells were treated with specific chemical
inhibitors for ERK (U0126), PI3K (LY294002), p38
(SB203580), and JNK (SP600125). When cells were
treated with 3 different concentrations of respective in-
hibitors, the axon length of CSMNs was reduced in a
dose-dependent manner by all agents except for
SP600125 (Fig. 6a-d). In all concentrations of chemical
a b c
d e f
Fig. 3 IT delivery of rAAV1-HGF ameliorated disease progression and prolonged the survival rate of SOD1-G93A TG mice. a-f SOD1-G93A TG mice
at P60 were intrathecally injected with 5 × 1011 GC of rAAV1-C or rAAV1-HGF. Behavioral tests including those for forelimb strength (a), hindlimb
strength (b), rotarod (c), and hanging wire (d) were performed, and body weight (e) was measured once a week until P158. In Fig. 3a-e, one-way
ANOVA was performed followed by Tukey’s post-hoc test at each time point. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. f Survival curve was
drawn based on Mantel-Cox and Gehan-Breslow-Wilcoxon tests for comparing two groups. In the Gehan-Breslow-Wilcoxon test, p value was
0.0115. Median survival days were 145.5 for the rAAV1-C-treated group, and 155 for the rAAV1-HGF-treated group. For graphs, values are
represented as mean ± SEM
Lee et al. Acta Neuropathologica Communications            (2019) 7:14 Page 9 of 18
inhibitors used in this experiment, cytotoxic effects were
not observed (Additional file 1: Figure S3a). These re-
sults suggested that ERK, PI3K, and p38 might play roles
in the HGF-mediated axonal outgrowth of CSMNs.
Effects of rHGF on ERK phosphorylation
We tested whether HGF could activate ERK, PI3K, and
p38 in the cortical culture. 3.2 × 106 cells were treated
with 100 ng/ml of rHGF, and 5 days later, total proteins
were extracted, followed by Western blot analysis. As
shown in Fig. 7a, the level of phosphorylated ERK was in-
creased by treatment with rHGF, while the levels of PI3K
and p38 were not affected. The effect of rHGF was inhib-
ited when cells were co-treated with 1 μM of PHA665752
or 10 μM of U0126 (Fig. 7b-c), suggesting that the
HGF-Met pathway is involved in the phosphorylation of
ERK in this cortical culture. We tested whether inhibition




Fig. 4 IT delivery of rAAV1-HGF led to histological improvements of SMNs and NMJs in SOD1-G93A TG mice. a-g non-TG or TG mice at P60 were
intrathecally injected with rAAV1-C or rAAV1-HGF. The LSCs (a-d) and TA muscles (e-f) were collected at P100, followed by IHC assay. a Representative
image of SMNs. Antibodies specific to ChAT and NeuN were used to label SMNs. b Number of SMNs per ventral horn was counted and represented as
a bar graph. c Proportion of SMNs per DAPI-positive cells was counted and represented as a bar graph. d Diameter of SMNs were measured and
represented as a bar graph. In, Fig. 4b-d, one-way ANOVA was performed, followed by Tukey’s post-hoc test. e-f The shape and integrity of NMJs were
determined as mentioned in Fig. 2 and represented as a bar graph. In Fig. 4e-f, two-way ANOVA was performed, followed by Tukey’s post-hoc test. In
Fig. 4e, ****p < 0.0001 for modified NMJ and ####p < 0.0001 for pretzel-shaped NMJ. In Fig. 4f, ****p < 0.0001 for fully innervated NMJ and ####p < 0.0001
for partially innervated NMJ. g Relative mass of TA was calculated using total body mass and represented as a bar graph. For bar graphs, values are
represented as mean ± SEM. For statistical analysis, one-way ANOVA was performed, followed by Tukey’s post-hoc test. For bar graphs,
*p < 0.05, **p < 0.005, ***p < 0.001, n.s. > 0.05. Scale bar: a = 50 μm
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axon length of CSMNs. As shown in Fig. 7d, treatment
with U0126 decreased the axon length of CSMNs
2.41-fold in the non-TG group and 2.03-fold in the TG
group, indicating that HGF could promote axonal out-
growth of CSMNs by specifically up-regulating phosphor-
ylation of ERK.
To test whether the above in vitro results were reprodu-
cible in vivo, 5 × 109 GC of viral vectors were intrathecally
injected into SOD1-G93A TG mice at P60, and the LSC
was analyzed for ERK. Compared with non-TG mice, the
level of phosphorylated ERK was increased 2.04-fold in
TG mice injected with a control vector, and was further
enhanced 5.54-fold when injected with AAV vectors
expressing HGF (Fig. 7e-f). There was no difference
in phosphorylation of other signaling molecules of the
HGF-Met pathway, such as STAT3, cJUN, and GSK3β
(Additional file 1: Figure S4a). These results indicated
that ERK might indeed be an important factor of the
HGF-mediated regeneration of motor neurons.
Effects of HGF-mediated ERK phosphorylation on levels of
ROS
To get an overall picture of the effects of HGF on gene
expression profile in CSMNs, cortical cells were treated
with 100 ng/ml of rHGF, and total RNAs were extracted
followed by microarray assay (Additional file 1: Figure S5a).
Among the 116 genes whose expression levels were chan-
ged more than 1.5-fold, 52 belonged to six major categor-
ies defined for fALS by Taylor et al., and 37 (71.15%) were
involved in the control of protein quality and RNA
metabolism [49]. Therefore, we tested whether the
HGF-Met-ERK signaling pathway could reduce
hSOD1 protein aggregation and/or oxidative stress.
Cortical cells were treated with rHGF, followed by
IHC to examine the distribution of mutant hSOD1.
When compared to the non-TG group containing no
hSOD1 aggregates, the proportion of CSMNs in the
TG group with hSOD1 aggregates was sharply increased to
0.4 ± 0.01 as shown in Fig. 8a-b. When treated with rHGF,
however, this proportion was reduced to 0.06 ± 0.02, while
it was increased to 0.3 ± 0.06 and 0.33 ± 0.04 by the
addition of inhibitors for Met (PHA665752) or ERK
(U0126), respectively (Fig. 8a).
Since the aggregated form of mutant hSOD1 could in-
crease oxidative stress, it was also tested whether the
rHGF-mediated reduction of protein aggregation could
alleviate oxidative stress by measuring hydrogen per-
oxide, peroxynitrite, hydroxyl radicals, nitric oxide,
a
b c d
Fig. 5 Treatment with rHGF enhanced the axonal outgrowth of CSMNs in motor cortical cultures. a-d SOD1-G93A TG mice were sacrificed at P3. After
dissociating motor cortices, 20,000 cells were seeded on 24-well plates. Three days later, cells were fixed and subjected to immunocytochemistry (ICC)
assay. a Representative image of CSMNs. Antibodies specific to UCHL1 (green) and Ctip2 (red, not shown) were used to label CSMNs. Serum-free
media was used as a control medium (C). Cells were visualized with confocal laser scanning microscopy. The axon length of CSMNs was measured
using Fiji software (yellow line). The axon length of CSMNs was measured after treatment with PHA665752, an inhibitor for Met (b) or rHGF (c) or rHGF
plus PHA665752 (d). For bar graphs, values are represented as mean ± SEM. In Fig. 5b-d, one-way ANOVA was performed, followed by Tukey’s post-
hoc test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Scale bar: a = 50 μm
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and peroxy radical in the cortical culture. Compared
to the control group treated with SFM, treatment
with rHGF decreased the level of oxidative stress by
34.22%, which was comparable to the effect (32.11%)
of N-acetyl-L-cysteine (NAC), a well-known scavenger of
oxygen free radical (Fig. 8c). Such HGF-mediated decrease
of oxidative stress was inhibited by 15.51 and 18.81%
when rHGF was co-treated with PHA665752 and U0126,
respectively (Fig. 8c).
To test whether the axonal outgrowth of CSMNs
could be promoted by alleviation of oxidative stress, the
effect of rHGF was tested in the presence of pyocyanin,
a ROS inducer. As shown in Fig. 8d, the axon length of
CSMNs was increased by 40.12% when treated with
NAC. The effect of rHGF was almost 3-fold greater at
118.83%, which was inhibited by 32.1% in the presence
of pyocyanin. Taken together, these results indicated that
HGF-mediated induction of ERK phosphorylation plays
an important role(s) in promoting the axonal outgrowth
of CSMNs by mitigating protein aggregation and oxida-
tive stress.
Discussion
In this report, we explored the possibility of delivering
the HGF gene by IT injection of rAAV vector for neuro-
muscular diseases. It was found that AAV serotype 1
could most effectively deliver and express the transgene
in the ventral horn. rAAV1-HGF produced the HGF
protein in a bell shape kinetics pattern over the course
of 16 weeks, with peak level achieved at 2 weeks
post-injection. In two neuromuscular disease models—
the sciatic nerve crush and SOD1-G93A TG mouse
models—a single administration of rAAV1-HGF into the
LSC improved motor functions and NMJ structure.
These results indicated that rAAV1 expressing HGF
might have regenerative potential and improve symp-
tomatic motor performance.
Of particular interest was the finding that IT injection
of rAAV1-HGF could not only facilitate protection of
but also delay the degeneration of motor neurons. In the
sciatic nerve crush model, for example, the regenerative
process takes place after Wallerian degeneration follow-
ing nerve injury, and rAAV1-HGF was shown to
a b
c d
Fig. 6 Inhibition of ERK, PI3K, and p38 resulted in decreased axonal outgrowth of CSMNs. a-d The axon length of CSMNs was measured and
represented as a bar graph after treatment with U0126 (ERK inhibitor) (a), LY294002 (PI3K inhibitor) (b), SB203580 (p38 inhibitor) (c), and SP600125
(JNK inhibitor) (d). For bar graphs, values are represented as mean ± SEM. In Fig. 6a-d, one-way ANOVA was performed, followed by Tukey’s post-
hoc test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n.s. > 0.05
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promote the regeneration of the sciatic nerves and the
recovery of NMJ structure. On the other hand, in the
SOD1-G93A TG mouse model, progressive degeneration
of motor neurons and muscles occurs, and rAAV1-HGF
could delay disease progression and degeneration of
SMNs. Therefore, rAAV1-HGF appears to provide dual
activities in the pathogenesis of motor neuron degener-
ation that may result in additive effects.
Our results are consistent with previous studies show-
ing the potentially positive roles of HGF or Met in ALS
patients or related animal models. Protein levels of HGF
and Met increase in the ventral horn of sALS patients at
the early stage, while patients with motor neurons de-
fective in HGF or Met are more susceptible to disease
progression of ALS, being atrophied rapidly [20]. In
SOD1-G93A TG mice, RNA levels of HGF and Met
were higher than the non-TG control, presumably to re-
spond to or compensate for pathological conditions [48].
In the same model, disease progression was shown to be
delayed and the survival rate to be increased when either
HGF or Met were overexpressed specifically in motor
neurons or when rHGF was injected into the spinal
cord. Together with our results, HGF appears to be a
strong candidate that may be used for developing thera-
peutics for ALS.
Although protein levels of HGF and Met have been
shown to increase in SOD1-G93A TG mice, the level of
biologically active forms of these proteins has not been
well studied in the LSC at the symptomatic stage. We
found that the level of phosphorylated Met was slightly
lower in SMNs of the ventral horn of SOD1-G93A TG
mice at P100, indicating that the level of endogenously
expressed HGF might not be sufficient to fully activate
Met. When TG mice were intrathecally injected with
rAAV1-HGF, however, the fraction of SMNs expressing
phosphorylated Met approximately doubled, suggesting
that exogenously added HGF could augment the activa-
tion of Met. Therefore, HGF appeared to produce
cell-autonomous effects by directly affecting SMNs.
HGF is also expected to generate non-autonomous ef-
fects by acting on glial cells such as astrocytes and
microglia. We previously showed that HGF produced
from plasmid DNA expression vector could lower the
level of ATF3 and CSF1 in DRG and change the distri-
bution of activated microglia in the dorsal horn in the
mouse chronic constriction injury model [33]. Others
also reported that treatment of primary astrocytes with
HGF in vitro reduced the protein level of EAAT2, a glu-
tamate transporter, and enhance the expression level of
total Met in reactive astrocytes in the spinal cord [20,
48]. We also observed that treatment with rHGF could
lower the levels of LPS-induced TNFα in the primary
astrocyte culture system (data not shown). Together
with the cell-autonomous effects described above, HGF
has, when properly delivered to patients, the potential to
generate powerful therapeutic effects by controlling two
of the most important pathways in the pathogenesis of
ALS and related motor neuron diseases.
Improvements in motor functions, NMJ morphology,
and the protection of SMNs observed in this study could
have resulted from 3 sources: changes in SMNs, in
upper motor neurons, or in a combination of both neu-
rons. HGF is known as a potent neurotrophic factor,
which can facilitate the proliferation, migration, differen-
tiation, and survival of sensory neurons, as well as motor
neurons [19, 26, 27, 34]. The interaction of HGF with
lower motor neurons has been relatively well character-
ized. For example, it has been reported that HGF could
function as a survival factor for SMNs in vitro [8, 54,
56]. In addition, HGF has also been shown to induce
remyelination of Schwann cells to promote axonal out-
growth of peripheral neurons [24]. These findings sug-
gested that HGF could directly and/or indirectly protect
damaged lower motor neurons.
On the other hand, the molecular mechanisms of
HGF’s interaction with upper motor neurons have been
poorly understood up until now. In this study, therefore,
we investigated the effects of HGF on upper motor neu-
rons in vitro, using the primary motor cortical culture
system consisting of CSMNs and glial cells. It was ob-
served that HGF could facilitate the axonal outgrowth of
CSMNs by controlling the phosphorylation of ERK.
When phenotypes of oxidative stress were analyzed
based on microarray data, treatment of CSMNs with
HGF protein was found to reduce the accumulation of
mutant SOD1 proteins and levels of oxidative stress
(See figure on previous page.)
Fig. 7 Phosphorylation of ERK was increased by treatment with HGF in the LSC and motor cortical cultures. a-c Motor cortices from non-TG or
TG mice at P3 were collected. After dissociation, cells were seeded on six-well plates with 3.2 × 106 cells/well. a Cells were treated with 100 ng/ml
of rHGF, and 5 days later, total proteins were isolated, followed by Western blot analysis. b-c Cells were treated with 1 μM of PHA665752 or 10 μM
of U0126. After 30 min, cells were treated with 100 ng/ml of rHGF, and five days later, total proteins were isolated followed by Western blot
analysis. DMSO was used as a negative control. d The axon length of CSMNs was measured and represented as a bar graph after co-treatment
with rHGF and U0126. For statistical analysis, one-way ANOVA was performed, followed by Tukey’s post-hoc test. e-f non-TG or TG mice at P60
were intrathecally injected with rAAV1-C or rAAV1-HGF. The LSCs were collected, and total proteins were extracted at P100, followed by Western
blot analysis (e). Relative levels of phosphorylated ERK were measured using Fiji software and represented as a bar graph (f). For bar graphs,
values are represented as mean ± SEM. For statistical analysis, one-way ANOVA was performed, followed by Tukey’s post-hoc test. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001
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factors such as H2O2, ONOO
−, HO, NO, and ROO. All
these effects were inhibited, however, when ERK phos-
phorylation was suppressed by U0126. These results sug-
gested that upper motor neurons could also have played
a role in the effects exerted by rAAV1-HGF, and that
ERK might be a key signaling factor involved.
It is also possible that HGF expressed from
rAAV1-HGF could have affected both spinal and upper
motor neurons, so observed improvements in the
SOD1-G93A TG mouse model might have come from
the combined effects. Our preliminary data indicated
that intramuscular injection of rAAV6-HGF into the
tibialis anterior did not have particularly visible effects
on motor functions and other parameters (data not
shown). Therefore, we are inclined to think that the role
of upper motor neurons may have been more important
in this particular model.
In summary, our data suggested that exogenously
added HGF, in the form of rAAV1-HGF intrathecally de-
livered to the LSC area, could improve behavioral de-
fects and survival rates in SOD1-G93A TG mice. ERK
activated by HGF from rAAV1-HGF appeared to play a
key role(s) in HGF-mediated effects such as alleviation
of oxidative stress and facilitation of protection, and
delay of degeneration of motor neurons. Taken together,
it appears that rAAV1-HGF may be developed as a novel
therapeutic agent for various diseases in which motor
neuron degeneration is the major pathologic cause.
Additional file
Additional file 1: Figure S1. Production of HGF-expressing rAAV vec-
tor. a To co-express two isoforms of HGF, HGF723 (or dHGF) and HGF728
(or cHGF), a gDNA-cDNA-hybrid sequence was generated. In this chimeric
sequence, a part of intron 4 of the HGF gene was inserted between
cDNA sequences of exon 4 and exon 5, allowing alternative splicing.
Since the length of intron 4 is relatively long, sequences between 246
and 4486 were deleted (Δ). The numbers represented indicate relative
positions of intron 4, and ‘1’ corresponds to the first nucleotide of intron
4. b 1.6x105 C2C12 cells were transduced with 1.23x108 GC of rAAV2, and
48 hours later, total RNAs were isolated followed by RT-PCR and acryl-
amide gel analysis. rAAV2-C lacking the HGF sequence was used as a
negative control (NC). The upper arrow indicates the amplicon size of
cHGF (142 bp), while the lower arrow shows the amplicon size of dHGF
(127 bp). c 8x104 C2C12 cells were transduced with 5x1013 GC of rAAV2,
and 48 hours later, supernatant was collected followed by ELISA for
hHGF. rAAV2-C lacking the HGF sequence was used as a negative control.
ND indicates that values were not detectable or lower than the minimum
detectable dose. d C57BL/6 mice at P60 were intrathecally injected with
5x109 GC of rAAV1-C or rAAV1-HGF. The LSCs, motor cortices, serum, and
TA were collected 8 weeks after injection and subjected to ELISA for
hHGF. For bar graphs, values are represented as mean ± SEM. Figure S2.
Levels of phosphorylated Met after IT delivery of rAAV1-HGF. a non-TG or
TG mice at P60 were intrathecally injected with 5x109 GC of rAAV1-C or
rAAV1-HGF. The LSCs were collected at P100. Tissues were fixed and sub-
jected to IHC assay. Antibodies specific to ChAT (green) and NeuN (red)
were used to label SMNs, together with those for p-Met (magenta). b
The proportion of SMNs expressing p-MET per total SMNs was measured
and represented as a bar graph. For bar graphs, values are represented as
mean ± SEM. Scale bar: a = 20 µm. *p < 0.05, n.s. > 0.05. Figure S3. Ef-
fects of rHGF or chemical inhibitors measured by WST1 assay in motor
cortical cells. a After dissociating motor cortices of P3 non-TG or TG mice,
1.6x105 cells were seeded on PDL-coated 48-well cell plates in the pres-
ence of rHGF or respective inhibitors. Three days later, WST1 assay was
performed. Cell viability was measured using a microplate reader and
represented as a bar graph. For the bar graph, values are represented as
mean ± SEM. n.s. > 0.05. Figure S4. Western blot analysis in the LSC
after IT delivery of rAAV1-HGF. a non-TG or TG mice at P60 were intra-
thecally injected with 5 × 109 GC of rAAV1-C or rAAV1-HGF. The LSCs
were collected at P100. Total proteins were extracted and subjected to
Western blot analysis. Figure S5. Microarray analysis of motor cortical
cells treated with rHGF. a Motor cortical cells were treated with 100 ng/
ml of rHGF for 3 days, followed by microarray analysis using Affymetrix
Genechip. SFM was used as a negative control (NC). After data extraction,
RMA normalization was performed followed by DEG analysis. Differential
expression was represented by color gradients. Genes were clustered
based on 6 major categories defined by Taylor et al., as described in Re-
sults. Genes involved in protein quality control are labeled in red, while
those related to RNA metabolism are labeled in blue. The rest of genes
are labeled in black. The NC group is for non-TG NC vs. TG NC, whereas
the rHGF group is for TG NC vs. TG rHGF. Table S1. Antibodies and
primers used in this study. a-b List of antibodies used for Western blot
analysis (a) and immunostaining (b). c List of primers used for murine IL2
and human SOD1 to determine the copy number of mhSOD1. F: Forward
primer, R: Reverse primer. (PPTX 7050 kb)
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Fig. 8 Treatment with rHGF reduced levels of protein aggregation and oxidative stress induced by mutant SOD1. a-b ICC assay was performed as
described in Fig. 5a. Antibodies specific to UCHL1 and Ctip2 were used to label CSMNs, together with those for hSOD1 (magenta). C: Treated
with SFM. In the hSOD1-stained panels, the cell boundaries of the CSMNs were outlined based on the UCHL1 signals, except for the panel in the
second row, where the cell boundaries are ambiguous. Proportion of hSOD1-positive cells per DAPI-positive cells was counted and represented
as a bar graph (b). For statistical analysis, one-way ANOVA was performed, followed by Tukey’s post hoc test. ****p < 0.0001 for non-TG SFM vs. TG
SFM, ###p < 0.001 for TG SFM vs. TG HGF, ++p < 0.01 for TG HGF vs. TG HGF + PHA665752 (or TG HGF + U0126). c 6.4 × 104 cells were seeded on
96-well plates. Cellular ROS levels were measured using a ROS detection kit and represented as a bar graph. Pyocyanin was used as an inducer of
ROS, whereas N-acetyl-L-cysteine (NAC) was employed as a scavenger of ROS. For statistical analysis, one-way ANOVA was performed, followed by
Tukey’s post-hoc test. ****p < 0.0001 for SFM vs. pyocyanin (or NAC or HGF), ##p < 0.01 for HGF vs. HGF + PHA665752, ###p < 0.001 for HGF vs.
HGF + U0126. d The axon length of CSMNs was measured and represented as a bar graph. For bar graphs, values are represented as mean ± SEM.
For statistical analysis, one-way ANOVA was performed, followed by Tukey’s post-hoc test. ****p < 0.0001 for non-TG SFM vs. TG SFM, ####p < 0.0001
for TG SFM vs. TG NAC (or TG HGF), ++++p < 0.0001 for TG HGF vs. TG HGF + pyocyanin. Scale bar: a = 20 μm
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